ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer

Lv, Shidong; Wu, Zeyu; Luo, Mayao; Zhang, Yifan; Zhang, Jianqiang; Pascal, Laura E.; Wang, Zhou*; Wei, Qiang*南方医科大学
Cell Death & Disease2022-9-1DOI: 10.1038/s41419-022-05182-0
6被引5阅读
引用收藏
分享

摘要

Ivermectin is a widely used antiparasitic drug and shows promising anticancer activity in various cancer types. Although multiple signaling pathways modulated by ivermectin have been identified in tumor cells, few studies have focused on the exact target of ivermectin. Herein, we report the pharmacological effects and targets of ivermectin in prostate cancer. Ivermectin caused G0/G1 cell cycle arrest, induced cell apoptosis and DNA damage, and decreased androgen receptor (AR) signaling in prostate cancer cells. Further in vivo analysis showed ivermectin could suppress 22RV1 xenograft progression. Using integrated omics profiling, including RNA-seq and thermal proteome profiling, the forkhead box protein A1 (FOXA1) and non-homologous end joining (NHEJ) repair executer Ku70/Ku80 were strongly suggested as direct targets of ivermectin in prostate cancer. The interaction of ivermectin and FOXA1 reduced the chromatin accessibility of AR signaling and the G0/G1 cell cycle regulator E2F1, leading to cell proliferation inhibition. The interaction of ivermectin and Ku70/Ku80 impaired the NHEJ repair ability. Cooperating with the downregulation of homologous recombination repair ability after AR signaling inhibition, ivermectin increased intracellular DNA double-strand breaks and finally triggered cell death. Our findings demonstrate the anticancer effect of ivermectin in prostate cancer, indicating that its use may be a new therapeutic approach for prostate cancer.

学科与关键词

关键词
ANTIPARASITIC AGENTDNA-REPAIRDRUGONCOGENE
相关
加载中…
  • Mithramycin suppresses DNA damage repair via targeting androgen receptor in prostate cancer
    Wang, Shan*; Gilbreath, Collin; Kollipara, Rahul K.; Sonavane, Rajni; Huo, Xiaofang; Yenerall, Paul; Das, Amit; Ma, Shihong; Raj, Ganesh, V; Kittler, Ralf*Cancer Letters, 2020, 488: 40-49.
  • Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.
    Chatterjee Payel; Schweizer Michael T; Lucas Jared M; Coleman Ilsa; Nyquist Michael D; Frank Sander B; Tharakan Robin; Mostaghel Elahe; Luo Jun; Pritchard Colin C; Lam Hung Ming; Corey Eva; Antonarakis Emmanuel S; Denmeade Samuel R; Nelson Peter SJournal of Clinical Investigation, 2019, 130.
  • Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer
    Zhou, Xumin; Zou, Libin; Chen, Wenbin; Yang, Taowei; Luo, Junqi; Wu, Kaihui; Shu, Fangpeng; Tan, Xiao; Yang, Yu; Cen, Shengren; Li, Chuanyin*; Mao, Xiangming*Pharmacological Research, 2021, 164: 105305.被引 41
查看全部 →

发表信息

论文状态
公开发表
期刊
Cell Death & Disease
发表日期
2022-09-01
卷期
第 13 卷, 第 9 期
页码
754
DOI
10.1038/s41419-022-05182-0
语言
ENGLISH
成果收录
SCIE
资助标注
China Postdoctoral Science Foundation [2020M682800]; National Natural Science Foundation of China [82103276]; Natural Science Foundation of Guangdong Province [2021A1515011023]; NIH [R50 CA211242]; Department of Urology, University of Pittsburgh

作者

  • L

    Lv, Shidong (第一作者)

    southern med univ

  • W

    Wu, Zeyu

    2

查看全部 8 位作者收起作者
  • L

    Luo, Mayao

    southern med univ

  • Z

    Zhang, Yifan

    southern med univ

  • Z

    Zhang, Jianqiang

    guangxi univ chinese med · southern med univ

  • P

    Pascal, Laura E.

  • W

    Wang, Zhou (通讯)

  • W

    Wei, Qiang (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417